Filtered By:
Source: American Heart Journal
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 59 results found since Jan 2013.
Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis; a nationwide population-based study
Conclusions In a nationwide cohort study with MHV and high TTR, heart failure and atrial fibrillation did not appear as risk factors of stroke/TE.
Source: American Heart Journal - August 11, 2016 Category: Cardiology Source Type: research
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.
Source: American Heart Journal - May 7, 2016 Category: Cardiology Source Type: research
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
Publication date: Available online 29 April 2016 Source:American Heart Journal Author(s): C. Camaro, S.A.J. Damen, M.A. Brouwer, E. Kedhi, S.W. Lee, M. Verdoia, L. Barbieri, A. Rognoni, A.W.J. van t Hof, E. Ligtenberg, M.J. de Boer, H. Suryapranata, G. De Luca Background The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with drug eluting stents (DES) is still under debate. Recent meta-analyses on≤6months versus 12months DAPT suggest that bleeding rates can be reduced, without a higher rate of thrombotic complications. In particular, the COMBO dual th...
Source: American Heart Journal - April 29, 2016 Category: Cardiology Source Type: research
Impact of Glycoprotein IIb/IIIa Inhibitors on the Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients with Acute Coronary Syndromes - Analysis from the PLATO (Platelet Inhibition and Patient Outcomes) Trial
Conclusions In patients with ACS undergoing early PCI the efficacy and safety of ticagrelor as compared with clopidogrel was not modified by GPI use according to the primary efficacy and safety endpoint of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs. with) GPI treatment.
Source: American Heart Journal - April 13, 2016 Category: Cardiology Source Type: research
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Publication date: April 2016 Source:American Heart Journal, Volume 174 Author(s): Thomas J. Povsic, Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, Charles Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to ...
Source: American Heart Journal - February 23, 2016 Category: Cardiology Source Type: research
Family History of Atrial Fibrillation is Associated with Earlier-onset and More Symptomatic Atrial Fibrillation: Results From the ORBIT-AF Registry
Conclusions Patients with a family history of AF developed AF at a younger age, had less comorbidity, and were more symptomatic. Once AF developed, no significantly increased risks of AF progression and thromboembolism were associated with a family history of AF compared with no family history.
Source: American Heart Journal - February 20, 2016 Category: Cardiology Source Type: research
Individualized approaches to thromboprophylaxis in atrial fibrillation
Publication date: March 2016 Source:American Heart Journal, Volume 173 Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in persons older than 55 years is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart rate control, and heart rhythm control comprise the 3 main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism, and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antagonist such as ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research
A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial
Conclusion In the FDA-approved cohort of the ENGAGE AF–-TIMI 48 trial, treatment with edoxaban 60/30 mg was superior to warfarin in the prevention of SSE and significantly reduced cardiovascular death and bleeding, especially fatal bleeding and hemorrhagic stroke.
Source: American Heart Journal - December 22, 2015 Category: Cardiology Source Type: research
Individualised approaches to thrombo-prophylaxis in atrial fibrillation
Publication date: Available online 11 November 2015 Source:American Heart Journal Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in adults over 55 years of age is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart-rate control, and heart-rhythm control comprise the three main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antag...
Source: American Heart Journal - November 12, 2015 Category: Cardiology Source Type: research
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research
Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis
Conclusion In patients with MHV on anticoagulation, eGFR is an independent predictor of major bleeding and death and not TE.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)
In conclusion, X-TRA and CLOT-AF will provide some answers to the many unresolved issues concerning patient outcomes and prognostic factors in patients with AF and LAA thrombi. Results from this study program would provide the first prospective interventional study (X-TRA) and a large international retrospective observational registry (CLOT-AF) on the prevalence and natural history of LA/LAA thrombi. Unique data on clot resolution with rivaroxaban in a prospective cohort would be obtained in X-TRA.
Source: American Heart Journal - January 6, 2015 Category: Cardiology Source Type: research
Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - December 2, 2014 Category: Cardiology Source Type: research
Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare duration of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - November 17, 2014 Category: Cardiology Source Type: research
